Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312085 | 1.00 | BDKRB1 (0.37) | BDKRB1CYP2D6CYP3A4USP2ALDH1A1 | |
| SCHEMBL3310098 | 0.94 | BDKRB1 (0.40) | BDKRB1CYP2D6CYP3A4USP2ALDH1A1 | |
| SCHEMBL3314543 | 0.93 | BDKRB1 (0.39) | BDKRB1CYP2D6CYP3A4USP2ALDH1A1 | |
| SCHEMBL3314535 | 0.93 | BDKRB1 (0.39) | BDKRB1CYP2D6CYP3A4USP2ALDH1A1 | |
| SCHEMBL3313142 | 0.88 | BDKRB1 (0.37) | BDKRB1CYP3A4ALDH1A1TSHR | |
| SCHEMBL3311026 | 0.86 | OPRM1 (0.44) | BDKRB1 | |
| SCHEMBL3409952 | 0.86 | BDKRB1 (0.44) | BDKRB1NPC1RAB9A | |
| SCHEMBL3311024 | 0.86 | OPRM1 (0.44) | BDKRB1 | |
| SCHEMBL5127947 | 0.84 | BDKRB1 (0.42) | BDKRB1ALDH1A1NPC1RAB9A | |
| SCHEMBL3413429 | 0.83 | BDKRB1 (0.45) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | claimed |
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | BDKRB1 1/4885CYP2D6 844/4885CYP3A4 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.